Cerebral Amyloid Imaging Using Florbetapir (AV-45) (IDEA3)

  • days left to enroll
  • participants needed
  • sponsor
    Centre Hospitalier Universitaire, Amiens
Updated on 24 January 2022
cognitive impairment
cognitive assessment


This study is aimed at examining the interest of amyloid radiotracer Florbetapir (18F-AV-45) for the etiological diagnosis of poststroke cognitive impairment and dementia


This study is aimed at examining the interest of amyloid radiotracer Florbetapir (18F-AV-45) for the etiological diagnosis of poststroke cognitive impairment and dementia. This study stems from two converging objectives: (1) the need to refine characteristics of vascular cognitive impairment (VCI) and dementia (VD) in order to propose diagnosis criteria of VCI and of mixed dementia and to improve diagnosis criteria of VD and (2) the need to improve the etiological diagnosis of poststroke cognitive impairment and dementia. It will take advantage from the ongoing GRECOG-VASC study (which determines the cognitive status 6 months poststroke in consecutive patients according to a standardized international battery) coordinated by the Amiens University Hospital center, the opportunity to perform amyloid imaging in vivo using Positron Emission Tomography (PET) and Florbetapir (a production site is located in the city of Amiens) and the collaboration between neurology and imaging departments of Amiens University hospital.

Condition Dementia, Cognition Disorders
Treatment florbetapir
Clinical Study IdentifierNCT02813434
SponsorCentre Hospitalier Universitaire, Amiens
Last Modified on24 January 2022


Yes No Not Sure

Inclusion Criteria

patients suffering of parenchymal stroke visualized by imaging (MRI)
patients suffering from cognitive impairment on the 6 months assessment (including GRECogVASC patients)
age between 40 and 80 years
reliable informant
agreeing to participate in the study
affiliation to a social security system

Exclusion Criteria

women of childbearing potential (defined as pre-menopausal, less than 2 years postmenopausal, or not surgically sterile), or who are breast-feeding
history of relevant severe drug allergy or hypersensitivity
patient receiving any investigational medications at least in the 30 last days
stroke affecting the cerebellum
mental retardation
dementia diagnosed before stroke
history of schizophrenia or psychiatric illness requiring a stay for > 2 days in a psychiatry unit
persons placed under judicial protection
comorbidities affecting cognition (respiratory, renal, liver, heart failure)
persistent disturbance of consciousness defined by a score to item 1a of the National Institute of Health Stroke Scale (NIHSS) 1
contraindication to MRI
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note